Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis

Journal of Neurochemistry

Volumn 92, Issue 6, 2005, Pages 1327-1339

  Mestre, Leyre ^a   Correa, Fernando ^a   Arévalo Martín, Angel ^a,d   Molina Holgado, Eduardo ^a,d   Valenti, Marta ^b   Ortar, Giorgio ^b,c   Di Marzo, Vincenzo ^b   Guaza, Carmen ^a  

^a INSTITUTO CAJAL   (Spain)

^b CNR   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

Author keywords

Endocannabinoid inactivation; Experimental multiple sclerosis; Macrophages

Indexed keywords

ANANDAMIDE; ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N OLEOYL 1' HYDROXYBENZYL 2' ETHANOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; INFLAMMATION; MACROPHAGE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD;

ANIMALS; ARACHIDONIC ACIDS; BENZYL COMPOUNDS; CARDIOVIRUS INFECTIONS; CARRIER PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; MICE; MICROGLIA; MOTOR ACTIVITY; MULTIPLE SCLEROSIS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; POLYUNSATURATED ALKAMIDES; THEILOVIRUS; UP-REGULATION;

EID: 15244359387     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02979.x     Document Type: Article

References (50)

1. Arévalo-Martín A., Vela J. M., Molina-Holgado E., Borrell J. and Guaza C. (2003) Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 23, 2511-2516.
2. Baker D., Pryce G., Croxford J. L., Brown P., Pertwee R. G., Huffman J. W. and Layward L. (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404, 84-87.
3. Baker D., Pryce G., Croxford J. L. et al. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300-302.
4. Berdyshev E. V. (2000) Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids 108, 169-190.
5. Bisogno T., Maurelli S., Melck D., De Petrocellis L. and Di Marzo V. (1997) Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272, 3315-3323.
6. Boullerne A. I., Nedelkoska L. and Benjamins J. A. (1999) Symergism of nitric oxide and iron in killing the transformed murine oligodendrocyte cell line N20.1. J. Neurochem. 72, 1050-1060.
7. Breivogel C. S., Griffin G., Di Marzo V. and Martin B. R. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60, 155-163.
8. Carrier E. J., Kearn C. S., Barkmeier A. J., Breese N. M., Yang W., Nithipatikom K., Pfister S. L., Campbell W. B. and Hillard C. J. (2004) Cultured rat microglial cells synthetize the endocannabinoid 2-arachidonoylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol. 65, 999-1007.
9. Compston A. and Coles A. (2002) Multiple Sclerosis. Lancet 359, 1221-1231.
10. Croxford J. L. and Miller S. D. (2003) Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+) WIN55,212. J. Clin. Invest. 111, 1231-1240.
11. Davies C. A., Loddick S. A., Touldmond S., Stroemer R. P., Hunt J. and Rothwell N. J. (1999) The progression and topographic distribution of interleukin-1 beta expression after permanent middle cerebral artery occlusion in the rat. J. Cereb. Blood Flow Metab. 19, 87-98.
12. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etingen A. and Mechoulam R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
13. Di Marzo V., Melck D., Bisogno T. and De Petrocellis L. (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521-528.
14. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J. A. and Kunos G. ( 1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264, 258-267.
15. Di Marzo V., Breivogel C. S., Tao Q., Bridgen D. T., Razdan R. K., Zimmer A. M., Zimmer A. and Martin B. R. (2000) Levels, metabolism and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75, 2434-2444.
16. Fontana A., Di Marzo V., Cadas H. and Piomelli D. (1995) Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. Prostaglandins Leukot. Essent. Fatty Acids 53, 301-308.
17. Howlett A. C., Barth F., Bonner T. I. et al. (2002) Classification of cannabinoid receptor. Pharmacol. Rev. 54, 161-202.
18. Hsieh C. S., Macatonia S. E., Tripp C. S., Wolf S. F., O'Garra A. and Murphy K. M. (1993) Development of Th1 CD4 T cells-through IL-12 produced by Listeria-induced macrophages. Science 260, 547-551.
19. Jeon Y. J., Yang K. H., Pulaski J. T. and Kaminski N. E. (1996) Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kappa B/Rel activation. Mol. Pharmacol. 50, 334-341.
20. Johnson R. T. (1994) The virology of demyelinating diseases. Ann. Neurol. 36, 54-60.
21. Klein T. W., Lane B., Newton C. and Friedman H. (2000) The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 225, 1-8.
22. Klein T. W., Newton C., Larsen K., Lu L., Perkins I., Nong L. and Friedman H. (2003) The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 1-11.
23. de Lago E., Ligresti A., Ortar G., Morera E., Cabranes A., Pryce G., Bifulco M., Baker D., Fernandez-Ruiz J. and Di Marzo V. (2004) In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur. J. Pharmacol. 484, 249-257.
24. Liu J., Bátkai S., Pacher P., Harvey-White J., Wagner J. A., Cravatt B. J., Gao B. and Kunos G. (2003) LPS induces anandamide synthesis in macrophages via CD14/MAPK/PI3K/NFkB independently of platelet activating factor. J. Biol. Chem. 278, 45 034-45 039.
25. Marsicano G., Goodenough S., Monory K. et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88.
26. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C. and Bonner T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
27. McCoy K. L., Matmeyeva M., Carlisle S. J. and Cabral G. A. (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther. 289, 1620-1625.
28. McGavern D. B., Zoecklein L., Drescher K. M. and Rodriguez M. (1999) Quantitative assessment of neurologic deficits in a chronic progressive murine model of CNS demyelination. Exp. Neurol. 158, 171-181.
29. McGavern D. B., Murray P. D., Rivera-Quiñones C., Schmelzer J. D., Low P. A. and Rodriguez M. (2000) Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 123, 519-531.
30. Mechoulam R., Ben Shabat S., Hanus L. et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
31. Miller S. D., Vanderlugt C. L., Begolka W. S., Pao W., Yauch R. L., Neville K. L., Katz-Levy Y., Carrizosa A. and Kim B. S. (1997) Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat. Med. 3, 1133-1136.
32. Mitrovic B., Ignarro L., Montestruque S., Smoll A. and Merrill J. E. (1995) Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cell in vitro. J. Neurosci. 61, 575-585.
33. Molina-Holgado F., Lledo A. and Guaza C. (1997) Anandamide suppresses nitric oxide and TNF-a responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8, 1929-1933.
34. Molina-Holgado E., Vela J. M., Arévalo-Martín A. and Guaza C. (2001) LPS/IFN-g cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10. Eur. J. Neurosci. 13, 493-502.
35. Molina-Holgado E., Vela J. M., Arévalo-Martín A., Molina-Holgado F., Almazán G., Borrell J. and Guaza C. (2002) Expression of cannabinoid CB1 receptors in oligodendroglial cells: activation of PI-3K/Akt signaling pathway promotes cell survival. J. Neurosci. 22, 9742-9753.
36. Molina-Holgado F., Pinteaux E., Moore J. D., Molina-Holgado E., Guaza C., Gibson R. M. and Rothwell N. J. (2003) Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23, 6470-6474.
37. Noseworthy J. H., Lucchinetti C., Rodriguez M. and Weinshenker B. G. (2000) Multiple sclerosis. New Engl. J. Med. 343, 938-952.
38. Olson J. K. and Girvin A. M. and. Miller S. D. (2001) Direct activation of innate and antigen-presenting functions of microglia following infection with Theiler's virus. J. Virol. 75, 9780-9789.
39. Ortar G., Ligresti A., de Petrocellis L., Morera E. and Di Marzo V. (2003) Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol. 65, 1475-1481.
40. Pena-Rossi C., Delcroix M., Huitinga I., McAllister A., Van Rooijen N., Claassen E. and Brahic M. (1997) Role of macrophages during Theiler's virus infection. J. Virol. 71, 3336-3340.
41. Pope J. G., Karpus W. J., Vanderlugt C. L. and Miller S. D. (1996) Flow cytometric and functional analysis of CNS-infiltrating cells in SJL/J mice with Theiler's virus-induced demyelinating disease: evidence for CD4 T cell-mediated pathology. J. Immunol. 156, 4050-4058.
42. Pryce G., Ahmed Z., Hankey D. J. R. et al. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126, 2191-2202.
43. Puffenbarger R. A., Boothe A. C. and Cabral G. A. (2000) Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29, 58-69.
44. Stefano G. B., Liu I. and Goligorsky M. S. (1996) Cannabinoid receptors are coupled to nitric oxide in invertebrate immunocytes, microglia, and human monocytes. J. Biol. Chem. 271, 19 238-19 242.
45. Wagner J. A., Varga K., Ellis E. F., Rzigalinski B. A., Martin B. R. and Kunos G. (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518-521.
46. Waksman Y., Olson J. M., Carlisle S. J. and Cabral G. (1999) The central cannabinoid receptor 8CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther. 288, 1357-1366.
47. Walter L. and Stella N. (2004) Cannabinoids and neuroinflammation. Br. J. Pharmacol. 2, 1-11.
48. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K. and Stella N. (2003) Nonsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23, 1398-1405.
49. Zajicek J., Fox P., Sanders H., Wright D., Vickery J., Nunn A. and Thompson A. (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMSstudy): multicentre randomised placeb-control trial. Lancet 362, 1517-1526.
50. Zheng I., Calenoff M. A. and Dal Canto M. C. (2001) Astrocytes and microglia are the main cells responsible for viral persistence in Theiler's virus encephalomyelitis infection leading to demyelination. J. Neuroimmunol. 118, 256-267.